DDInter551 DDInter1628
Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Diflunisal {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Diflunisal {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Diflunisal {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) CAMK1D
CAMK1D {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Diflunisal {u} (Compound) resembles {v} (Compound) Salsalate
Salsalate {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Diflunisal {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) ZNF451
ZNF451 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Diflunisal {u} (Compound) resembles {v} (Compound) Salicylic acid
Salicylic acid {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Diflunisal {u} (Compound) resembles {v} (Compound) Salsalate
Salsalate {u} (Compound) causes {v} (Side Effect) Haemoglobin
Haemoglobin {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Diflunisal {u} (Compound) resembles {v} (Compound) Niclosamide
Niclosamide {u} (Compound) upregulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Diflunisal {u} (Compound) resembles {v} (Compound) Salicylic acid
Salicylic acid {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Diflunisal {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) regulates {v} (Gene) C2CD2L
C2CD2L {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Diflunisal (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Diflunisal (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Diflunisal (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by CAMK1D (Gene) and CAMK1D (Gene) is bound by Ruxolitinib (Compound)
Diflunisal (Compound) resembles Salsalate (Compound) and Salsalate (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Diflunisal (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by ZNF451 (Gene) and ZNF451 (Gene) is upregulated by Ruxolitinib (Compound)
Diflunisal (Compound) resembles Salicylic acid (Compound) and Salicylic acid (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Diflunisal (Compound) resembles Salsalate (Compound) and Salsalate (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Ruxolitinib (Compound)
Diflunisal (Compound) resembles Niclosamide (Compound) and Niclosamide (Compound) upregulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Ruxolitinib (Compound)
Diflunisal (Compound) resembles Salicylic acid (Compound) and Salicylic acid (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Ruxolitinib (Compound)
Diflunisal (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) regulates C2CD2L (Gene) and C2CD2L (Gene) is upregulated by Ruxolitinib (Compound)